Clinical Trial Detail

NCT ID NCT02459119
Title Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Alabama at Birmingham
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.